[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353483-105":59,"doc-detail-353483-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","risk-of-neoplasms-with-semaglutide-in-patients-with-type-2-diabetes-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials","Risk of neoplasms with semaglutide in patients with type 2 diabetes - a systematic review and meta-analysis of randomized controlled trials","","Semaglutide prescribed with diet and exercise improves glycemic control in adults with type 2 diabetes, yet its potential tumorigenesis impact remains debated. A systematic review and meta-analysis following PRISMA 2020 evaluated randomized controlled trials using Web of Science, PubMed, Embase, and ScienceDirect. Nineteen RCTs (38,160 participants) assessed overall, benign, and malignant neoplasm risks via odds ratios and 95% confidence intervals, including sensitivity and publication bias tests.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/risk-of-neoplasms-with-semaglutide-in-patients-with-type-2-diabetes-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/353483/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/risk-of-neoplasms-with-semaglutide-in-patients-with-type-2-diabetes-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/353483.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main question of the meta-analysis?","Question",{"text":113,"@type":114},"Whether semaglutide use in patients with type 2 diabetes is associated with the risk of overall, benign, and malignant neoplasms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the randomized controlled trials identified and analyzed?",{"text":118,"@type":114},"Eligible RCTs were searched in Web of Science, PubMed, Embase, and ScienceDirect and analyzed according to PRISMA 2020, with pooled odds ratios and 95% confidence intervals, plus sensitivity analyses and publication bias assessments.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the pooled results show for different types of neoplasms?",{"text":122,"@type":114},"Semaglutide was associated with increased risk of overall neoplasms and benign neoplasms, while no statistically significant association was found for malignant neoplasms.",{"name":124,"@type":111,"acceptedAnswer":125},"What do the findings imply for clinical practice and future research?",{"text":126,"@type":114},"Clinicians should maintain clinical awareness of potential neoplastic risks, and further long-term RCTs are needed to clarify clinical significance.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},353483,1790185076,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","OPEN ACCESS  \nEDITED BY  \nAbdulmuminu Isah,  \nUniversity of Nigeria, Nsukka, Nigeria  \nREVIEWED BY  \nRosaria Maddalena Ruggeri, University of Messina, Italy Abid Shaheer,  \nGulf Medical University, United Arab Emirates  \n*CORRESPONDENCE  \nCangui Wu,  \n [1109419575@qq.com](1109419575@qq.com)  \nRECEIVED 23 June 2026  \nREVISED 15 July 2026  \nACCEPTED 07 August 2026  \nPUBLISHED 03 September 2026  \nCITATION  \nZhong Y, Tan X, Zhang L and Wu C (2026) Risk of neoplasms with semaglutide inpatients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.  \nFront. Pharmacol. 17:1916932 .  \ndoi: 10.3389/fphar.2026.1916932  \nCOPYRIGHT  \n© 2026 Zhong, Tan, Zhang and Wu. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTYPE Systematic Review PUBLISHED 03 September 2026 DOI 10.3389/fphar.2026.1916932  \nRisk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials  \nYuanyuan Zhong 1, Xing Tan 1, Ling Zhang 1 and Cangui Wu 2*  \n1Department of Pharmacy, The Third People’s Hospital of Yunnan Province, The Second Affiliated Hospital of Dali University, Kunming, Yunnan, China, 2Department of Breast Oncology, Jieyang People’s Hospital, Jieyang, Guangdong, China  \nBackground: Semaglutide is prescribed in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes (T2DM) . However, its potential impact on tumorigenesis has prompted considerable debate. Methods: The meta-analysis was conducted in accordance with PRISMA 2020 guidelines. We searched Web of Science, PubMed, Embase, and ScienceDirect for eligible randomized controlled trials (RCTs) . The outcome was the risk of overall, benign and malignant neoplasms. The pooled results were expressed as odds ratio (OR) with 95% confidence interval (95% CI) . Influential publication was determined by performing the sensitivity analysis. Publication bias was assessed using the funnel plot, Begg’s and Egger’s tests. Results: Nineteen RCTs conducted between 2016 and 2025 were included, enrolling of 38,160 patients with T2DM. The interventions involved subcutaneous semaglutide and oral semaglutide, with treatment durations ranging from 26 to 156 weeks. Fixedeffects meta-analysis revealed thatsemaglutide use was associated with an increased risk of overall neoplasms (OR = 1.19, 95% CI = 1.07 to 1.32, P = 0.001) and benign neoplasms (OR = 1.28, 95% CI = 1.02 to 1.61, P = 0.032), but showed no significant association with malignant neoplasms (OR = 1.12, 95% CI = 1.00 to 1.26, P = 0.054) . No influential publications or significant publication bias were detected. Conclusion: Semaglutide use in patients with T2DM is associated with a modestly increased risk of overall and benign neoplasms, but not malignant neoplasms. These findings highlight the importance of maintaining clinical awareness regarding potential neoplastic risks, and further long-term RCTs are warranted to clarify their clinical significance.  \nSystematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/view/](https://www.crd.york.ac.uk/PROSPERO/view/)[ ](https://www.crd.york.ac.uk/PROSPERO/view/)[CRD420261354386](CRD420261354386), Identifier CRD420261354386 .  \nKEYWORDS  \nGLP-1 receptor agonists, neoplasms risk, randomized controlled trials, semaglutide, type 2 diabetes  \n1 Introduction  \nType 2 diabetes mellitus (T2DM) constitutes a pervasive systemic metabolic disorder and represents a critical global public health challenge. According to projections by the International Diabetes Federation, the glob","cbCaigR6Wit0PjBW","https://ap.wps.com/l/cbCaigR6Wit0PjBW","pdf",5436758,11,"English","# Introduction\n## Background\n# Methods\n## Search strategy and eligible studies\n## Outcomes and statistical analysis\n# Results\n## Included trials and participant characteristics\n## Overall, benign, and malignant neoplasm risks\n## Sensitivity and publication bias\n# Conclusion","[{\"question\":\"What was the main question of the meta-analysis?\",\"answer\":\"Whether semaglutide use in patients with type 2 diabetes is associated with the risk of overall, benign, and malignant neoplasms.\"},{\"question\":\"How were the randomized controlled trials identified and analyzed?\",\"answer\":\"Eligible RCTs were searched in Web of Science, PubMed, Embase, and ScienceDirect and analyzed according to PRISMA 2020, with pooled odds ratios and 95% confidence intervals, plus sensitivity analyses and publication bias assessments.\"},{\"question\":\"What did the pooled results show for different types of neoplasms?\",\"answer\":\"Semaglutide was associated with increased risk of overall neoplasms and benign neoplasms, while no statistically significant association was found for malignant neoplasms.\"},{\"question\":\"What do the findings imply for clinical practice and future research?\",\"answer\":\"Clinicians should maintain clinical awareness of potential neoplastic risks, and further long-term RCTs are needed to clarify clinical significance.\"}]","Risk of neoplasms with semaglutide in patients with type 2 diabetes - a systematic review and meta-analysis of randomized controlled trials | PDF",1790105663,28,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b46034d1df6d52285bb3ec2ed01d0cdf.webp",983,1390,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c5eac3d6f73138ad7dfb2d28b8aaefd.webp",982,1388,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e28a2354e94ef054f2d0470578d59ed.webp",981,1387,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f532cce4b3e78111bd52bb933b01111f.webp",980,1385]